Last reviewed 2026-06-02 · How we verify

TQB2450(blank)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3 active Small molecule ✓ Verified May 2026

TQB2450(blank) is a PD-1 inhibitor Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. It is currently in Phase 3 development for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

TQB2450 is a monoclonal antibody targeting PD-1.

TQB2450 is an antibody being studied in clinical trials for the treatment of Stage III Non-small-cell Lung Cancer and Extensive Small Cell Lung Cancer. It is being compared to Anlotinib and a placebo in a randomized, double-blind study.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TQB2450(blank)
Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Drug class	PD-1 inhibitor
Target	PD-1
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

TQB2450 works by binding to PD-1, a protein on the surface of immune cells, thereby blocking its interaction with its ligands PD-L1 and PD-L2. This blockade releases the brakes on the immune system, allowing it to attack cancer cells more effectively.

Approved indications

Non-small cell lung cancer, PD-L1 positive
Head and neck squamous cell carcinoma

Common side effects

Fatigue
Diarrhea
Nausea
Rash
Pyrexia

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TQB2450(blank) CI brief — competitive landscape report
TQB2450(blank) updates RSS · CI watch RSS
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI

Frequently asked questions about TQB2450(blank)

What is TQB2450(blank)?

TQB2450(blank) is a PD-1 inhibitor drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., indicated for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

How does TQB2450(blank) work?

TQB2450 is a monoclonal antibody targeting PD-1.

What is TQB2450(blank) used for?

TQB2450(blank) is indicated for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

Who makes TQB2450(blank)?

TQB2450(blank) is developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (see full Chia Tai Tianqing Pharmaceutical Group Co., Ltd. pipeline at /company/chia-tai-tianqing-pharmaceutical-group-co-ltd).

What drug class is TQB2450(blank) in?

TQB2450(blank) belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is TQB2450(blank) in?

TQB2450(blank) is in Phase 3.

What are the side effects of TQB2450(blank)?

Common side effects of TQB2450(blank) include Fatigue, Diarrhea, Nausea, Rash, Pyrexia.

What does TQB2450(blank) target?

TQB2450(blank) targets PD-1 and is a PD-1 inhibitor.

Drug class: All PD-1 inhibitor drugs
Target: All drugs targeting PD-1
Manufacturer: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Non-small cell lung cancer, PD-L1 positive
Indication: Drugs for Head and neck squamous cell carcinoma

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing